Global Situation of Dengue and Dengue Haemorrhagic Fever by Leduc James
118 Trop. Med., 36 (4), 118-121, December, 1994
Global Situation of Dengue and Dengue Haemorrhagic Fever
James LEDUC
Programmeon Bcaterial, Viral Diseases and Immunology, Division of Communicable
Diseases, World Health Organization Headquarters, Geneva, Switzerland
Keywords: Global situation, dengue, dengue haemorrhagic fever
Dengue, and the severe complications, dengue haemorrhagic fever (DHF) and dengue
shock syndrome (DSS), are the most important arbovirus diseases in the world today. Indeed,
there is a global pandemic of these diseases in progress throughout the tropical and sub-
tropical regions of the world. Over the past several decades, there has been a dramatic in-
crease in both the geographic distribution and the incidence of these diseases. As an exam-
ple, for the 25 year period 1956 to 1980, the average number of DHF cases per year was
less than 30,000. During the following five year period, this rate increased nearly five-fold, to
almost 150,000 cases per year, and in the next five year period, 1986 to 1990, the number of
cases increased an additional two-fold.
The reasons for this increase in dengue and DHF may be found in four societal
changes: increased urbanization leading to more densely populated areas; increased air travel,
leading to rapid dissemination of new serotypes of dengue virus into susceptible populations;
changes in lifestyle that have lead to increase availability of vector mosquito breeding sites;
and humanpopulation growth resulting in an increase in the susceptible population. These
changes have been most dramatic in southeast Asia since the end of World War E, and the
increases in dengue and DHF have been most dramatic there as well. These societal changes
have been accompanied by entomological changes during the past 20 years that have resulted
in increases in the density of the primary dengue vector mosquito, Aedes aegypti, and a
reinfestation of the Americas by this species, following the aborted attempt at its eradication
from the hemisphere.
Dengue and DHF/DSS have followed a progression in southeast Asia, first with the in-
itial appearance of DHF/DSS, followed by sporadic cases leading to an endemic situation
with cases seen every year, and in certain areas with all four dengue serotypes present most
or all of the time. This pattern has progressed from a few countries affected in the Region in
the 1950's and 1960's, to most countries from India to southern China now affected.
The pattern of expansion of dengue and DHF/DSS seen in southeast Asia is being
repeated today in the Americas. The similarities in events leading to endemic DHF are ap-
parent, with the Americas experiencing a dramatic increase in Ae. aegypti distribution and
density, increased dengue transmission, the introduction of multiple dengue serotypes, fre-
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quent dengue epidemics, the first appearance of DHF, and finally epidemics of DHF. The
cornerstone to the introduction and evolution of dengue and DHF in the Americas has been
the dramatic reinfestation of the Americas by Ae. aegypti. At the termination of the Ae. aegyp-
ti eradication campaign, this species was found in only a few countries of northern South
America, the Caribbean, and the southeastern United States. Over the following 20 years, vir-
tually every locality where the mosquito had been eliminated during the eradication campaign
was reinfested. Today, both the distribution and density of Ae. aegypti is as great, or even
greater, than it was prior to the eradication campaign. This abundance of a competent mos-
quito vector, coupled with the societal changes already mentioned, has resulted in to a situa-
tion in the Americas similar to that experienced in southeast Asia 20 years or so ago.
It is likely that similar events are unfolding in much of tropical and subtropical Africa;
however, data is limited on the existence of dengue and DHF there, although some major out-
breaks have been reported recently.
Clearly the challenges of this global pandemic of dengue and DHF/DSS demand im-
mediate and coordinate action. Three approaches are nowbeing pursued by WHO to address
this emergency. These are improved, sustainable vector control, increased training, and vac-
cine development.
The key to sustainable control of Ae. aegypti rests with community involvement, since
this mosquuito species is highly adapted to life in close association with humans. It breeds in
water holding containers in and around the home, and readily enters houses to feed and rest.
Consequently, control efforts must rely to a large extent in convincing people that they must
personally eliminate vector breeding around their homes by control of potential mosquito
breeding sites. These efforts should be integrated with other vector control resources, such
as entomological surveillance, insecticide applications and personal protective measures,
especially during outbreak situations. Clearly active entomological surveillance efforts are re-
quired to monitor vector population densities and organize effective interventions if outbreaks
are to be prevented.
Training plays a critical part in dengue prevention and control programmes.
Workshops for health care providers that focus on the appropriate treatment of DHF/DSS
patients have clearly been shown to save lives. Clinicians who are familiar with the clinical
course of DHF/DSS are much better prepared to effectively treat these patients as compared
to those without past experience or appropriate training. Likewise, parents must be made
aware of the critical warning signs of DHF/DSS, so that they will bring their sick children to
the hospital at the first sign of shock. Finally, public educational campaigns are needed to en-
sure that the population at risk understands how the disease is spread, its clinical
characteristics, and preventive measures. These efforts, when coupled with improved
laboratory diagnostic capabilities and effective surveillance of disease and vectors, can
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significantly reduces the risk of dengue and DHF/DSS.
As reagents are not commercially available for the laboratory diagnosis of dengue and
DHF/DSS, WHO is attempting to develop regional sources for routine use. Efforts at
regional self sufficiency in dengue reagents will require assistance from the network of WHO
Collaborating Centres for Virus Reference and Research.
Although a protective vaccine is not yet available for dengue, good progress has been
made, and vaccination may play a role in the future prevention of dengue. The problem of
vaccine development for dengue and DHF/DSS is complicated by the fact that four distinct
viruses may cause dengue and DHF/DSS, there is not protective cross protection between
these different serotypes, and the risk of severe DHF/DSS is substantially greater among
those suffering a second of subsequent infection with dengue. Consequently, any vaccine
must protect against all four dengue serotypes.
Candidate live, attenuated vaccines to all four dengue virus serotypes have been
developed by Dr Natth Bhamarapravati and his colleagues at Mahidol University in Thailand
with the support of WHO and others. Preliminary results indicate that these vaccines are
safe and immunogenic, eliciting good neutralizing antibody responses when administered to
humans. Serological follow-up of individuals receiving candidate vaccines indicates that
neutralizing antibodies persist for at least five years following inoculation, the current length
of follow-up. While efficacy tests have not been attempted, it is generally believed that
neutralizing antibodies are a good indication of protection. Experiments to determine the
stability of candidate vaccines in vector mosquitoes, Ae. aegypti, found that a high titer of vac-
cine virus was required to infect feeding mosquitoes, generally higher than that seem among
vaccinated persons. In addition, the candidate vaccine viruses failed to replicate well in vec-
tor mosquitoes, and when examined following growth in mosquitoes, it was determined that
the candidate vaccines retained their attenuated characteristics. Commercial production of
these candidate dengue vaccines is under development, with formal efficacy testing planned
for the near future.
In addition to the efforts of the team at Mahidol University, the WHO Global Pro-
grammeon Vaccines has for several years supported an effort to develop vaccines to dengue
and Japanese encephalitis (JE) using molecular technology. At present, the most promising
approaches have been expression of virus-like particles from engineered vaccinia constructs
that contain a portion of the Pre-M and E genes of dengue and JE viruses. Other approaches
have included expression of structural and non-structural components in baculovirus expres-
sion systems, development of chimeric viruses, and purification of subunit particles. Only the
expression of virus-like particles by recombinant vaccinia has reached the stage of human
testing.
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In summary, dengue and DHF/DSS are of growing importance throughout the tropics
and subtropics. Their increase is due to societal changes and dramatic increases in both the
distribution and density of the primary vector mosquito of dengue, Ae. aegypti. To combat
this threat, the WHO is focusing on sustained vector control, expanded training oppor-
tunities, enhance surveillance and laboratory capabilities, and vaccine development efforts.
These programmes will require active participation, not only by members of the health care
professions, but also by the community members themselves.
